According to the newly released ELN Guideline for AML, FLT3 inhibitors have been recommended for intensive chemotherapy at induction, consolidation, maintenance and salvage stages of FLT3‐mutated patients.38 The gene discussed is FLT3; the disease is acute myeloid leukemia.